Literature DB >> 10543754

Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.

E J Goldstein1, D M Citron, C Vreni Merriam, K Tyrrell, Y Warren.   

Abstract

The activities of gemifloxacin (SB 265805, LB20304) and comparator agents were determined by an agar dilution method against 419 clinical strains of less-commonly identified species of anaerobes. Gemifloxacin was generally more active than trovafloxacin against gram-positive strains by one to two dilutions. Peptostreptococci (Peptostreptococcus asaccharolyticus, Peptostreptococcus magnus, Peptostreptococcus micros, and Peptostreptococcus prevotii) and Porphyromonas spp. (Porphyromonas asaccharolytica, Porphyromonas canoris, Porphyromonas gingivalis, and Porphyromonas macacae) were all susceptible to </=0.25 microgram of gemifloxacin per ml. The MICs of gemifloxacin at which 90% of the following strains were inhibited (MIC(90)s) were </=2 microgram/ml: Actinomyces israelii, Actinomyces odontolyticus, Clostridium innocuum, Clostridium clostridioforme, Anaerobiospirillum spp., Bacteroides tectum, Bacteroides ureolyticus, Bacteroides gracilis (now Campylobacter gracilis), Prevotella intermedia, Prevotella heparinolytica, and the Prevotella oris-buccae group. Fusobacterium naviforme and Fusobacterium necrophorum were also susceptible to </=2 microgram of gemifloxacin per ml, while Fusobacterium varium strains exhibited a bimodal pattern; the other Fusobacterium species, such as Fusobacterium ulcerans and Fusobacterium russii, as well as Veillonella spp., the Prevotella melaninogenica group, Prevotella bivia, Clostridium difficile, and Bilophila wadsworthia were relatively resistant to gemifloxacin (MIC(90)s, >/=4 microgram/ml).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543754      PMCID: PMC89550     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  International multicenter investigation of LB20304, a new fluoronaphthyridone.

Authors:  Annik F. Hohl; Reno Frei; Verena Pünter; Alexander von Graevenitz; Cynthia Knapp; John Washington; David Johnson; Ronald N. Jones
Journal:  Clin Microbiol Infect       Date:  1998-05       Impact factor: 8.067

2.  Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria.

Authors:  F Marco; M S Barrett; R N Jones
Journal:  J Antimicrob Chemother       Date:  1997-10       Impact factor: 5.790

3.  In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.

Authors:  J I Oh; K S Paek; M J Ahn; M Y Kim; C Y Hong; I C Kim; J H Kwak
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.

Authors:  M G Cormican; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  In vitro activity of gemifloxacin (SB 265805) against anaerobes.

Authors:  E J Goldstein; D M Citron; Y Warren; K Tyrrell; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

6.  Characterization of saccharolytic Bacteroides and Prevotella isolates from infected dog and cat bite wounds in humans.

Authors:  C J Alexander; D M Citron; S Hunt Gerardo; M C Claros; D Talan; E J Goldstein
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

7.  Frequency of isolation of Porphyromonas species from infected dog and cat bite wounds in humans and their characterization by biochemical tests and arbitrarily primed-polymerase chain reaction fingerprinting.

Authors:  D M Citron; S Hunt Gerardo; M C Claros; F Abrahamian; D Talan; E J Goldstein
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

  7 in total
  8 in total

1.  Comparative in vitro activities of gemifloxacin, other quinolones, and nonquinolone antimicrobials against obligately anaerobic bacteria.

Authors:  N Kleinkauf; G Ackermann; R Schaumann; A C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Periodontal bacteria in rabbit mandibular and maxillary abscesses.

Authors:  Kerin L Tyrrell; Diane M Citron; Jeffrey R Jenkins; Ellie J C Goldstein
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 3.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Bloodstream infection with Anaerobiospirillum succiniciproducens: a potentially lethal infection.

Authors:  Theodoros Kelesidis
Journal:  South Med J       Date:  2011-03       Impact factor: 0.954

5.  First report of treatment of Anaerobiospirillum succiniciproducens bloodstream infection with levofloxacin.

Authors:  Theodoros Kelesidis; Jennifer Dien Bard; Romney Humphries; Kevin Ward; Michael A Lewinski; Daniel Z Uslan
Journal:  J Clin Microbiol       Date:  2010-03-19       Impact factor: 5.948

6.  Clostridium clostridioforme: a mixture of three clinically important species.

Authors:  S M Finegold; Y Song; C Liu; D W Hecht; P Summanen; E Könönen; S D Allen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-05       Impact factor: 3.267

7.  Minimum requirements for a rapid and reliable routine identification and antibiogram of Fusobacterium necrophorum.

Authors:  A Jensen; L Hagelskjaer Kristensen; H Nielsen; J Prag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-16       Impact factor: 3.267

Review 8.  Clostridium innocuum: Microbiological and clinical characteristics of a potential emerging pathogen.

Authors:  Kathryn E Cherny; Emily B Muscat; Megan E Reyna; Larry K Kociolek
Journal:  Anaerobe       Date:  2021-07-28       Impact factor: 3.331

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.